Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)

Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwig, Heinz, Hausmann, Bela, Schreder, Martin, Pönisch, Wolfram, Zojer, Niklas, Knop, Stefan, Gunsilius, Eberhard, Egle, Alexander, Petzer, Andreas, Einsele, Hermann, Hajek, Roman, Weisel, Katja, Krenosz, Karl Jochen, Lang, Alois, Lechner, Daniel, Greil, Richard, Berry, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176146/
https://www.ncbi.nlm.nih.gov/pubmed/35846090
http://dx.doi.org/10.1002/jha2.130
_version_ 1784722601037266944
author Ludwig, Heinz
Hausmann, Bela
Schreder, Martin
Pönisch, Wolfram
Zojer, Niklas
Knop, Stefan
Gunsilius, Eberhard
Egle, Alexander
Petzer, Andreas
Einsele, Hermann
Hajek, Roman
Weisel, Katja
Krenosz, Karl Jochen
Lang, Alois
Lechner, Daniel
Greil, Richard
Berry, David
author_facet Ludwig, Heinz
Hausmann, Bela
Schreder, Martin
Pönisch, Wolfram
Zojer, Niklas
Knop, Stefan
Gunsilius, Eberhard
Egle, Alexander
Petzer, Andreas
Einsele, Hermann
Hajek, Roman
Weisel, Katja
Krenosz, Karl Jochen
Lang, Alois
Lechner, Daniel
Greil, Richard
Berry, David
author_sort Ludwig, Heinz
collection PubMed
description Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression‐free survival (PFS) (10.2 vs 8.5 months, P = .04), particularly in patients with very long (>75% quartile) PFS . Additionally, alpha diversity was lower in patients with progressive disease (P < .05). These findings suggest an interrelationship between the oral microbiome and outcome in patients with MM and encourage a novel direction for diagnostic and/or therapeutic strategies.
format Online
Article
Text
id pubmed-9176146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91761462022-07-14 Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial) Ludwig, Heinz Hausmann, Bela Schreder, Martin Pönisch, Wolfram Zojer, Niklas Knop, Stefan Gunsilius, Eberhard Egle, Alexander Petzer, Andreas Einsele, Hermann Hajek, Roman Weisel, Katja Krenosz, Karl Jochen Lang, Alois Lechner, Daniel Greil, Richard Berry, David EJHaem Short Reports Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression‐free survival (PFS) (10.2 vs 8.5 months, P = .04), particularly in patients with very long (>75% quartile) PFS . Additionally, alpha diversity was lower in patients with progressive disease (P < .05). These findings suggest an interrelationship between the oral microbiome and outcome in patients with MM and encourage a novel direction for diagnostic and/or therapeutic strategies. John Wiley and Sons Inc. 2020-11-08 /pmc/articles/PMC9176146/ /pubmed/35846090 http://dx.doi.org/10.1002/jha2.130 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Ludwig, Heinz
Hausmann, Bela
Schreder, Martin
Pönisch, Wolfram
Zojer, Niklas
Knop, Stefan
Gunsilius, Eberhard
Egle, Alexander
Petzer, Andreas
Einsele, Hermann
Hajek, Roman
Weisel, Katja
Krenosz, Karl Jochen
Lang, Alois
Lechner, Daniel
Greil, Richard
Berry, David
Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
title Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
title_full Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
title_fullStr Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
title_full_unstemmed Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
title_short Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
title_sort reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (agmt mm 1, phase ii trial)
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176146/
https://www.ncbi.nlm.nih.gov/pubmed/35846090
http://dx.doi.org/10.1002/jha2.130
work_keys_str_mv AT ludwigheinz reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT hausmannbela reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT schredermartin reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT ponischwolfram reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT zojerniklas reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT knopstefan reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT gunsiliuseberhard reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT eglealexander reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT petzerandreas reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT einselehermann reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT hajekroman reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT weiselkatja reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT krenoszkarljochen reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT langalois reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT lechnerdaniel reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT greilrichard reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial
AT berrydavid reducedalphadiversityoftheoralmicrobiomecorrelateswithshortprogressionfreesurvivalinpatientswithrelapsedrefractorymultiplemyelomatreatedwithixazomibbasedtherapyagmtmm1phaseiitrial

Ejemplares similares